PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy

Yang, Zhenlin; Xu, Jiachen; Li, Renda; Gao, Yibo

doi:10.1007/s00432-019-03023-w

Cited by 25 publications

(42 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, CD47 has not been previously investigated as a potential NPC biomarker. We found that the positive expression rate of CD47 protein was 56.1% in NPC tissues, which is consistent with its expression rate in breast cancer, 10 pulmonary sarcomatoid carcinoma, 12 and head and neck squamous cell carcinoma. 20 Thereafter, we explored the associations between CD47 expression and clinicopathological characteristics, along with the prognostic value of CD47 expression, in NPC patients.…”

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

<p>CD47 Overexpression Is Associated with Epstein–Barr Virus Infection and Poor Prognosis in Patients with Nasopharyngeal Carcinoma</p>

Wang¹,

Pei²,

Zhu³

et al. 2020

OTT

View full text Add to dashboard Cite

Little is known about the clinical significance of CD47 expression and its association with Epstein-Barr virus (EBV) infection in patients with nasopharyngeal carcinoma (NPC). The aim of this study was to clarify the prognostic value and role of CD47 in EBV-associated NPC. Materials and Methods: Sixty-six cases of non-metastatic NPC were retrospectively reviewed. Tissues were collected for immunohistochemical staining of CD47 and the EBVencoded oncoprotein latent membrane protein 1 (LMP1). Western blotting and quantitative real-time PCR were performed to determine the CD47 and LMP1 levels in common human NPC cell lines. Additionally, CD47 and LMP1 expression in a constructed EBV-positive human NPC cell (CNE-2-EBV+) and a stable cell line transfected with LMP1 plasmid (CNE-2-LMP1) was assessed. Next, we used Western blotting to assess the decrease in CD47 expression on CNE-2-LMP1 cells after transfecting them with small interfering RNA (siRNA)-targeting LMP1. Results: In NPC patients, CD47 overexpression was significantly associated with disease recurrence (P=0.010), leading to poorer disease-free survival (DFS; P=0.002) and overall survival (P=0.021). Multivariate Cox proportional hazards models demonstrated that CD47 (HR=5.452, P=0.016) was an independent prognostic factor of DFS. Moreover, CD47 expression was associated with plasma EBV-DNA copy number and LMP1 tissue expression. Among the human NPC cell lines, CD47 and LMP1 expression was notably higher in the EBV-positive C666-1 cell line than in the EBV-negative cell lines. Furthermore, EBV infection upregulated CD47 expression via LMP1-mediated pathways in human NPC cells. Conclusion: This study indicated that CD47 is related to EBV infection in NPC patients, and it is a feasible biomarker.

show abstract

Section: Discussionsupporting

confidence: 82%

“…9 Several studies have demonstrated that high CD47 expression predicts poor prognosis in several cancers. [10][11][12][13][14] However, little is known about the expression and role of CD47 in NPC.…”

Section: Introductionmentioning

confidence: 99%

<p>CD47 Overexpression Is Associated with Epstein–Barr Virus Infection and Poor Prognosis in Patients with Nasopharyngeal Carcinoma</p>

Wang¹,

Pei²,

Zhu³

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…14,60 There is a significant correlation between PD-L1 expression and CD47 and PD-L1 co-expression, the density of CD8(+) T lymphocytes (p = 0.004, 0.012) and CD68(+) macrophages (p = 0.026, 0.034) is higher. 14 and PHF20-NTRK1 fusion. 7,45,52 There also have case report of KRAS/TP53/ STK11 co-mutations.…”

Section: Pd-1/pd-l1mentioning

confidence: 97%

“…24 Other studies reported similar overall 5-year survival rates, that is, approximately 11-25%, 9,19,25 the median reported OS of 148 patients was 22.5 months (range from 0.9 months to 102.4 months). 14 Some studies demonstrated a fairly low rate of 5-year survival in PSC (pathological stage [pStage] I: 16.3%, n = 49) compared with other NSCLCs (pStage I adenocarcinoma 81.8%, and pStage I squamous-cell carcinoma 70.2%). 3 In patients with advanced disease, OS has no correlation with race, age, sex, smoking, tumor size, N stage, pleural invasion, or lymphatic metastasis.…”

Section: Clinical Featuresmentioning

confidence: 99%

Pulmonary sarcomatoid carcinoma: progress, treatment and expectations

Liu

et al. 2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

Pulmonary sarcomatoid carcinoma (PSC) is a unique, highly invasive pulmonary malignancy with a poor prognosis, representing 0.1–0.4% of all malignant lung tumors. Because of its highly aggressive character and propensity for frequent metastasis, PSC shows low response rates to traditional treatments such as chemotherapy, radiotherapy, and neoadjuvant therapy. In recent years, considerable progress has been made in gene sequencing, targeted therapies, and immunotherapies. One of the most promising treatment approaches is the selection of mono-targeted or multi-targeted drugs according to tumor gene-mutation sites, such as epidermal growth factor receptor or vascular endothelial growth factor receptor 2 ( EGFR/VEGFR2), anaplastic lymphoma kinase ( ALK), and others. Another approach is the activation of therapeutic anti-tumor immunity via pathways including programmed cell-death protein-1/programmed cell-death ligand-1 ( PD-1/PD-L1), which has been used in individual cases. In this review, we will introduce the clinicopathologic features, molecular typing, and traditional treatments. We will also review the biological characteristics and the latest therapies for PSC. These novel therapies show promise in the management of PSC, and the outcomes of investigative trials will hopefully reveal a variety of treatment options for patients with PSC.

show abstract

“…The mutations in Kirsten rat sarcoma viral oncogene homolog gene (KRAS) with or without tumour protein p53 gene mutations were associated with decreased survival probability and local metastases 49 . A retrospective review of 148 PSC patients who underwent surgeries showed that 36.5% and 52.7% of them were positive for PD‐L1 and the cluster of differentiation 47 (CD47), whereas 24.3% demonstrated PD‐L1/CD47 co‐expression which correlated with poorer prognosis 50 …”

Section: Details Of the Casementioning

confidence: 99%

Anti‐PD‐1 antibody camrelizumab plus doxorubicin showed durable response in pulmonary sarcomatoid carcinoma: Case report and literature review

et al. 2020

View full text Add to dashboard Cite

What is known and objective Pulmonary sarcomatoid carcinoma (PSC) is characterized by dismal prognosis and resistance to platinum‐based chemotherapy. The immune checkpoint inhibitors showed promising efficacy in the treatment of PSC. Camrelizumab is a programmed cell death protein 1 inhibitor; however, current evidence of its efficacy in PSC is lacking. Case summary A 47‐year‐old female non‐smoker presented with central‐type masses in the right upper and lower lobes. PSC (cT4N2M0, stage IIIB) with positive expression of programmed death ligand‐1 was diagnosed. First‐line camrelizumab plus doxorubicin and cisplatin was introduced, followed by camrelizumab monotherapy due to grade 4 leukopenia and thrombocytopenia during the combination therapy. The lesions indicated a partial remission which endured for more than 20 months. What is new and conclusion Camrelizumab plus doxorubicin and cisplatin regimen is a promising option for PSC patients. Further high‐quality trials are warranted.

show abstract

PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy

Cited by 25 publications

References 47 publications

<p>CD47 Overexpression Is Associated with Epstein–Barr Virus Infection and Poor Prognosis in Patients with Nasopharyngeal Carcinoma</p>

<p>CD47 Overexpression Is Associated with Epstein–Barr Virus Infection and Poor Prognosis in Patients with Nasopharyngeal Carcinoma</p>

Pulmonary sarcomatoid carcinoma: progress, treatment and expectations

Anti‐PD‐1 antibody camrelizumab plus doxorubicin showed durable response in pulmonary sarcomatoid carcinoma: Case report and literature review

Contact Info

Product

Resources

About